Novel Approaches for Systemic Mastocytosis

Luke Fletcher, Uma Borate

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: The purpose of this review is to summarize the pathophysiology of systemic mastocytosis, review the most recent clinical trials and drug development in systemic mastocytosis, with a specific focus on the advanced systemic mastocytosis subtypes. RECENT FINDINGS: Systemic mastocytosis is a clonal neoplasm of mast cells that has had a number of successful therapeutic options being developed in the past few years. The first therapeutic agent to be Food and Drug Administration (FDA) approved in decades was midostaurin in 2017 with a 60% response rate % with improvement in both end-organ damage and symptoms. However, complete responses/remissions with midostaurin have been elusive. Additional clinical trials of tyrosine kinase inhibitors that target the proto-oncogene receptor tyrosine kinase (KIT) mutation show great promise. The two drugs with promising early clinical trial data include avapritinib and DCC-2618 with avapritinib showing potential to induce complete remissions. SUMMARY: Therapies for systemic mastocytosis are in a stage of evolution with further elucidation of additional mutations associated with oncogenesis in addition to the most commonly described KIT (give details), ongoing clinical trials could potentially with lead to further targeted therapy and increased complete responses and durable remissions.

Original languageEnglish (US)
Pages (from-to)112-118
Number of pages7
JournalCurrent Opinion in Hematology
Volume26
Issue number2
DOIs
StatePublished - Mar 1 2019

Fingerprint

Systemic Mastocytosis
4'-N-benzoylstaurosporine
Clinical Trials
Mutation
Proto-Oncogenes
Receptor Protein-Tyrosine Kinases
United States Food and Drug Administration
Therapeutics
Mast Cells
Pharmaceutical Preparations
Protein-Tyrosine Kinases
Carcinogenesis
Neoplasms

ASJC Scopus subject areas

  • Hematology

Cite this

Novel Approaches for Systemic Mastocytosis. / Fletcher, Luke; Borate, Uma.

In: Current Opinion in Hematology, Vol. 26, No. 2, 01.03.2019, p. 112-118.

Research output: Contribution to journalArticle

Fletcher, Luke ; Borate, Uma. / Novel Approaches for Systemic Mastocytosis. In: Current Opinion in Hematology. 2019 ; Vol. 26, No. 2. pp. 112-118.
@article{8c88cbb456a04efcb6147a2c09bc9b23,
title = "Novel Approaches for Systemic Mastocytosis",
abstract = "PURPOSE OF REVIEW: The purpose of this review is to summarize the pathophysiology of systemic mastocytosis, review the most recent clinical trials and drug development in systemic mastocytosis, with a specific focus on the advanced systemic mastocytosis subtypes. RECENT FINDINGS: Systemic mastocytosis is a clonal neoplasm of mast cells that has had a number of successful therapeutic options being developed in the past few years. The first therapeutic agent to be Food and Drug Administration (FDA) approved in decades was midostaurin in 2017 with a 60{\%} response rate {\%} with improvement in both end-organ damage and symptoms. However, complete responses/remissions with midostaurin have been elusive. Additional clinical trials of tyrosine kinase inhibitors that target the proto-oncogene receptor tyrosine kinase (KIT) mutation show great promise. The two drugs with promising early clinical trial data include avapritinib and DCC-2618 with avapritinib showing potential to induce complete remissions. SUMMARY: Therapies for systemic mastocytosis are in a stage of evolution with further elucidation of additional mutations associated with oncogenesis in addition to the most commonly described KIT (give details), ongoing clinical trials could potentially with lead to further targeted therapy and increased complete responses and durable remissions.",
author = "Luke Fletcher and Uma Borate",
year = "2019",
month = "3",
day = "1",
doi = "10.1097/MOH.0000000000000486",
language = "English (US)",
volume = "26",
pages = "112--118",
journal = "Current Opinion in Hematology",
issn = "1065-6251",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Novel Approaches for Systemic Mastocytosis

AU - Fletcher, Luke

AU - Borate, Uma

PY - 2019/3/1

Y1 - 2019/3/1

N2 - PURPOSE OF REVIEW: The purpose of this review is to summarize the pathophysiology of systemic mastocytosis, review the most recent clinical trials and drug development in systemic mastocytosis, with a specific focus on the advanced systemic mastocytosis subtypes. RECENT FINDINGS: Systemic mastocytosis is a clonal neoplasm of mast cells that has had a number of successful therapeutic options being developed in the past few years. The first therapeutic agent to be Food and Drug Administration (FDA) approved in decades was midostaurin in 2017 with a 60% response rate % with improvement in both end-organ damage and symptoms. However, complete responses/remissions with midostaurin have been elusive. Additional clinical trials of tyrosine kinase inhibitors that target the proto-oncogene receptor tyrosine kinase (KIT) mutation show great promise. The two drugs with promising early clinical trial data include avapritinib and DCC-2618 with avapritinib showing potential to induce complete remissions. SUMMARY: Therapies for systemic mastocytosis are in a stage of evolution with further elucidation of additional mutations associated with oncogenesis in addition to the most commonly described KIT (give details), ongoing clinical trials could potentially with lead to further targeted therapy and increased complete responses and durable remissions.

AB - PURPOSE OF REVIEW: The purpose of this review is to summarize the pathophysiology of systemic mastocytosis, review the most recent clinical trials and drug development in systemic mastocytosis, with a specific focus on the advanced systemic mastocytosis subtypes. RECENT FINDINGS: Systemic mastocytosis is a clonal neoplasm of mast cells that has had a number of successful therapeutic options being developed in the past few years. The first therapeutic agent to be Food and Drug Administration (FDA) approved in decades was midostaurin in 2017 with a 60% response rate % with improvement in both end-organ damage and symptoms. However, complete responses/remissions with midostaurin have been elusive. Additional clinical trials of tyrosine kinase inhibitors that target the proto-oncogene receptor tyrosine kinase (KIT) mutation show great promise. The two drugs with promising early clinical trial data include avapritinib and DCC-2618 with avapritinib showing potential to induce complete remissions. SUMMARY: Therapies for systemic mastocytosis are in a stage of evolution with further elucidation of additional mutations associated with oncogenesis in addition to the most commonly described KIT (give details), ongoing clinical trials could potentially with lead to further targeted therapy and increased complete responses and durable remissions.

UR - http://www.scopus.com/inward/record.url?scp=85060778502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060778502&partnerID=8YFLogxK

U2 - 10.1097/MOH.0000000000000486

DO - 10.1097/MOH.0000000000000486

M3 - Article

VL - 26

SP - 112

EP - 118

JO - Current Opinion in Hematology

JF - Current Opinion in Hematology

SN - 1065-6251

IS - 2

ER -